IgA nephropathy (IgAN) is one of the most common glomerular diseases world-wide. Its natural history is consistent with a clinical onset in the first decades of life. Clinical indicators of poor prognosis are proteinuria and hypertension. Angiotensin-converting enzyme-inhibitors (ACE-I) are a promising treatment, since angiotensin II playes a key role in glomerular hypertension and permselectivity and modulates mesangial and tubular cell functions. This concerned action was designed to evaluate the effect of ACE-I (benazepril 0.2mg/Kg) verus placebo in young IgAN patients (<35 years, proteinuria >/=1g/day/=50 ml/min/1.73m2). Activity and chronicity indexes are evaluated on renal biopsies together with the spatial distribution of IgA and C3 deposits by confocal microscopy. Ambulatory blood pressure measurements allow the identification of medium-high pressure levels. Enrolled patients are investigated for factors modulating the disease progression, including genetic predictors (gene polymorphism of HLA, IgA switch region, ACE, AT1 receptor, adducin, complement factors) and immunologic parameters (aberrantly glycosylated and macromolecular IgA in serum and cytokine urinary excretion).
Book Description
Product Details
Would you like to update product info or give feedback on images?
|
Customer Reviews
|
There are no customer reviews yet.
|
|||
|
Video reviews
|
Tag this product(What's this?)Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organize and find favorite items. |
Sell a Digital Version of This Book in the Kindle Store
If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store.
Learn more
Customer Discussions
|
This product's forum
Active discussions in related forums
Search Customer Discussions
|
Related forums
|
